WCLC 2022 | Highlights from the IASLC 2022 World Conference on Lung Cancer congress

Julia Rotow, MD, Dana-Farber Cancer Institute, Boston, MA, shares her highlights from the IASLC 2022 World Conference on Lung Cancer congress, including data presented on KRASG12C combinations such as a low-dose KRAS inhibitor with pembrolizumab which demonstrated responses in patients who had progressed on checkpoint inhibitors. Additionally, data on hepatotoxicity of KRAS inhibition when combined with checkpoint inhibitors, either when given concurrently or following treatment with checkpoint inhibitors is discussed. Dr Rotow also mentions the novel bispecific antibody (BiTE), tarlatamab, which is under investigation in small cell lung cancer (SCLC) and currently demonstrating encouraging results. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.